Genitourinary Cancers

The explosion of new checkpoint immunotherapy drugs has changed the paradigm of care for patients with urothelial carcinoma, the most common form of bladder cancer.

The FDA’s Oncologic Drugs Advisory Committee voted 17-0 to recommend approval for ABP-215, a biosimilar for bevacizumab (Avastin) to treat a range of solid tumors.

Daniel P. Petrylak, MD, professor of Medicine and Urology, Yale Cancer Center, discusses combinations with pembrolizumab (Keytruda) for patients with urothelial carcinoma.

Simon Chowdhury, MA, MBBS, MRCP, PhD, consultant medical oncologist specializing in urological cancer, Sarah Cannon Research Institute, United Kingdom, discusses what roles pazopanib (Votrient) and pembrolizumab (Keytruda) have as monotherapy for patients with renal cell carcinoma (RCC).

Patients with metastatic renal cell carcinoma had an objective response rate of 40% and a 2-year overall survival rate of nearly 70% with the immune checkpoint combination of ipilimumab (Yervoy) and nivolumab (Opdivo), in phase I results from CheckMate-016.

Arjun V. Balar, MD, assistant professor of medicine, Division of Hematology and Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses the approval of pembrolizumab (Keytruda) in bladder cancer.

Jorge Garcia, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses the optimal sequence of immunotherapies for the treatment of patients with bladder cancer.

Shilpa Gupta, MD, MBBS, discusses the future of drug therapies for kidney cancer, and the challenges facing the research landscape.

Gennaday Bratslavsky, MD, discusses the evaluation and management of RCC and highlighted genetic testing for the patient’s family.

Andrea Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses the combination of cabozantinib (Cabometyx) plus nivolumab (Opdivo) in patients with urothelial carcinoma.

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses the potential of immunotherapy as an adjuvant treatment for patients with renal cell carcinoma (RCC).

The vision and dedication to training future urologic surgeons and advancing care by these giants of urology should never go unrecognized, underappreciated, or forgotten.

Brian Rini, MD, discusses additional adjuvant trials that have perplexed the field, what potential immunotherapy could have in this setting, and other obstacles to tackle in the renal cell carcinoma landscape.

Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of oncology and medicine, Georgetown University School of Medicine, discusses the results of a trial of atezolizumab (Tecentriq) plus bevacizumab (Avastin) in renal cell carcinoma.

Costas Lallas, MD, discusses the current role of immunotherapy for patients with genitourinary cancers, the potential for immunotherapy in combination with chemotherapy, and how the rise of immunotherapy affects all providers treating patients with these malignancies.

Andrea Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses the side effects of cabozantinib (Cabometyx) plus immunotherapy agents in bladder cancer.

Updated phase II results from the KEYNOTE-052 trial showed that first-line treatment with pembrolizumab (Keytruda) produced a long-lasting response for patients with cisplatin-ineligible advanced urothelial cancer.

Moshe Ornstein, MD, discusses the obstacles physicians are facing with the use of immunotherapy for patients with renal cell carcinoma.

The Committee for Medicinal Products for Human Use has adopted a positive opinion recommending marketing authorization of tivozanib for adult patients with advanced renal cell carcinoma.

Primo N. Lara, MD, associate director for translational research, UC Davis Comprehensive Cancer Center, discusses epacadostat plus pembrolizumab (Keytruda) in patients with metastatic renal cell carcinoma (RCC).

Jorge Garcia, MD, discusses how the field of bladder cancer has transformed with the FDA approval of pembrolizumab, and how oncologists should choose between 5 checkpoint inhibitors now available for the second-line setting and beyond.

Eric Jonasch, MD, professor, The University of Texas MD Anderson Cancer Center, discusses the potential of immunotherapy for patients with sarcomatoid renal cell carcinoma (RCC).

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses the updated findings of the KEYNOTE-045 trial of pembrolizumab (Keytruda) in urothelial carcinoma.